Article
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
Leukemia research - 1 Jun 2024
Mohebbi Alireza, Shahriyary Fahimeh, Farrokhi Vida, Bandar Bita, Saki Najmaldin
Abstract excerpt
BACKGROUND: Acute myeloid leukemia (AML) is a complex disease with diverse mutations, including prevalent mutations in the FMS-like receptor tyrosine kinase 3 (FLT3) gene that lead to poor prognosis. Recent advancements have introduced FLT3 inhibitors that have improved outcomes for FLT3-mutated AML patients, however, questions remain on their application in complex conditions such as relapsed/refractory (R/R)...
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Leukemia, Myeloid, Acute
- Protein Kinase Inhibitors
- Drug Resistance, Neoplasm
- Mutation
- Aniline Compounds
- Phenylurea Compounds
- Neoplasm Recurrence, Local
- Pyrazines